Nutritional interventions, epigenetics, and structural research gaps in Neurofibromatosis Type 1 — and why the science isn't missing, the money is.
Peer-reviewed evidence documents that vitamin D deficiency inversely correlates with neurofibroma burden, that curcumin combined with a Mediterranean diet produced measurable tumor reduction in a pilot study, and that NF1-deficient tissue exhibits a lipid storage phenotype rescuable by dietary intervention in animal models.
Yet no randomised controlled trial of any nutritional intervention for NF1 tumors has been completed.
The reason is not scientific impossibility. It is economics. Natural compounds cannot be patented. Without patent protection, no pharmaceutical company will invest the $50–100 million required for a Phase 3 clinical trial. The absence of large RCTs for curcumin, vitamin D, quercetin, or EGCG in NF1 is not evidence that these compounds do not work. It is evidence that the funding model is broken.
This research hub synthesises the full evidence base across seven domains: amygdalin/laetrile evidence and the Sloan-Kettering controversy; direct NF1 nutritional studies including curcumin, vitamin D, and lipid metabolism; bioactive compounds with NF1 pathway relevance; epigenetic mechanisms including twin discordance; current pharmaceutical treatments and their limitations; structural incentives shaping research priorities; and traditional food-as-medicine systems with modern scientific validation.
11 NF1 patients over 6 months. The combination group (1200 mg/day curcumin + Mediterranean diet) showed: 51% reduction in cutaneous neurofibromas in one patient (212→110), 30% reduction in another, and 28.2% volume reduction of a cranial plexiform neurofibroma confirmed by MRI.
Neither diet alone nor curcumin alone produced the effect. Only the combination worked — the diet enhanced curcumin bioavailability dramatically.
No larger trial has been funded since 2017. Nine years of silence. A Phase 1 trial has finally opened at the University of Minnesota, funded by charity — not pharma.
NF1 patients: 14.0 ng/mL vs controls: 31.4 ng/mL (p<0.0001). Inverse correlation with number of dermal neurofibromas (ρ = −0.572, p<0.00001). 93.5% of NF1 patients had low vitamin D. In vitro, vitamin D analogues inhibited neurofibroma cell growth by 40–70%.
No large prospective RCT evaluating vitamin D supplementation's effect on neurofibroma growth has been conducted. Vitamin D is cheap, unpatentable, and available at any pharmacy. That is the explanation.
NF1-deficient muscle accumulates excessive lipid — a metabolic phenotype, not just genetic. A diet of medium-chain fatty acids + L-carnitine produced 45% increase in grip strength and 71% reduction in intramyocellular lipid in mice. Confirmed in Phase 2a human trial (6 NF1 children) — safe, feasible, trends toward improved strength. Also improved bone mineral density.
The researchers' own conclusion: NF1 is a lipid storage disease treatable by dietary intervention. Published in a peer-reviewed journal. Not fringe. Not alternative. Yet attracted a fraction of the attention given to $269K/year drugs.
NF1 deficiency drives excessive reactive oxygen species through constitutive RAS activation. Even asymptomatic NF1 patients show increased oxidative DNA damage. If NF1 patients live in chronic oxidative stress, and antioxidant compounds modulate the very pathway NF1 leaves uncontrolled, the question is not "why would diet matter?" but "why has nobody properly tested it?"
A Children's Tumor Foundation survey found ~25% of NF1 respondents regularly take dietary supplements for NF symptoms. Turmeric/curcumin and bee propolis were most common for plexiform neurofibromas. They are experimenting because the system offers them nothing else for cutaneous neurofibromas. They deserve better evidence. They are not getting it. [Source]
"Spontaneous mutation" is not a scientific explanation. It is a label for ignorance — science saying "we don't know why" dressed up in Latin to sound like an answer. The same establishment that demands faith-based traditions show evidence accepts this label without question. It receives the same unexamined acceptance that science accuses faith of having.
The most compelling explanation: selfish spermatogonial selection. NF1 mutations give sperm stem cells a proliferative advantage through RAS/MAPK activation, enriching mutant sperm over time. ~90% of spontaneous NF1 mutations originate in the paternal genome.
NanoSeq duplex sequencing of 81 sperm samples confirmed NF1 is under significant positive selection — not random at all. NF1 mutations are transmitted at 61.1% rather than the expected 50%.
MZ twins with the same NF1 mutation show: high concordance for café-au-lait spots (PC=0.89) but significant discordance for plexiform neurofibromas (PC=0.40). All 8 MZ twin pairs studied had significant intra-pair differences in NF1 promoter methylation. Higher methylation correlated with optic glioma discordance.
If identical twins with the same mutation have different disease severities linked to different methylation patterns, then environment — diet, stress, exposure — matters. Yet nobody is studying what modifiable factors drive those methylation differences.
Multiple microRNAs (miR-128, miR-137, miR-193b, miR-107) directly regulate NF1 expression. In MPNST transformation, 90 differentially expressed miRNAs have been identified. Cutaneous and plexiform neurofibromas are epigenetically distinct. Environmental factors that modify miRNA expression — including diet, stress, and toxin exposure — could therefore modulate NF1 severity. [Garza-Manero et al., 2021]
NF1 loss means constitutive RAS/MAPK activation. Several natural compounds directly target this pathway — but none have been tested in NF1 patients, because none are patentable.
Decreased phospho-ERK1/2 and phospho-MEK1/2 levels by 60% at 60 minutes in H-ras-transformed cells — the exact pathway constitutively activated in NF1. Green tea costs pennies. Nobody will fund the trial.
Selectively degrades oncogenic RAS (H-RAS, K-RAS) without affecting wild-type RAS. More potent MEK1 inhibitor than the synthetic PD098059. Found in onions, apples, berries. Unpatentable. No NF1 study exists.
High-dose DHA induced apoptosis in malignant peripheral nerve sheath tumor cells — the only direct NF1-relevant fatty acid study. Omega-6 (arachidonic acid) had the opposite effect, stimulating growth.
AKBA from Boswellia promotes Schwann cell proliferation and increases ERK phosphorylation — the opposite of what NF1 patients need. Despite popularity in brain tumor communities, NF1 patients should exercise caution. This is why rigorous research matters — and why its absence is dangerous.
Intestinal Bacteroides drives glioma progression in NF1 mouse models. Glioma growth reduced under germ-free conditions. What you eat shapes your microbiome → your microbiome shapes your immune environment → your immune environment drives or restrains NF1 tumor growth. Traditional food cultures rich in fermented foods support exactly the microbial diversity that modern Western diets have depleted.
The question is not "Does nutrition affect NF1?" The evidence says it does. The question is "Why has nobody properly tested it?" The answer is structural.
The FDA approved OxyContin in 1995 without long-term studies and without assessment of addictive capabilities. Dr. Curtis Wright IV, the FDA review officer, allowed Purdue Pharma to help draft his review. He approved label language stating delayed absorption "is believed to reduce abuse liability" — no data supported this. Wright resigned ~1 year later and joined Purdue Pharma at $379,000+/year. Purdue made over $35 billion in OxyContin sales.
Dr. David Graham (FDA's own Associate Director for Science) testified before the Senate that Vioxx was "the single greatest drug safety catastrophe in the history of this country" — 88,000–139,000 heart attacks/strokes, 44% fatality rate. Graham stated the FDA was "broken" and "incapable of protecting America."
This is the same agency that banned laetrile on safety grounds. The same agency that has not funded a single RCT of curcumin for NF1. The same agency that approved a drug costing $269,000/year with a 20% response rate and side effects including cardiomyopathy. The safety standard is not applied equally. These are not conspiracy theories — they are congressional testimonies, published papers, and court records.
Natural compounds cannot be patented. Without patents, no company will invest $50–100M in a Phase 3 trial because generic manufacturers can copy the result. A BMJ analysis stated: "The current system provides little incentives to study and develop less expensive nondrug interventions, although they may often be preferable." Industry spends more on marketing than R&D.
First FDA-approved NF1 therapy (2020). For plexiform neurofibromas only. Side effects in ≥40%: vomiting, rash, pain, diarrhoea. Serious: cardiomyopathy, ocular toxicity. Continuous indefinite treatment. Adult Phase 3 response: only 20%.
41% adult response rate (vs selumetinib's 20%). CNS-penetrant. Still plexiform only. Still indefinite. Still significant side effects.
Cutaneous neurofibromas affect ~100% of NF1 patients by adulthood. Patients identify them as their greatest disease burden. Zero approved therapies exist. The curcumin/Mediterranean diet pilot is, to date, the only intervention showing reduction in cutaneous neurofibromas in any published study. It used supermarket ingredients. It cost nothing. It has been ignored for nine years.
Ramadan fasting — dawn-to-dusk for 30 days — is one of the most studied intermittent fasting protocols. Research shows it lowers IGF-1 and mTOR while increasing AMPK and upregulating tumor-suppressor TP53 — pathways directly relevant to NF1 biology.
The Prophetic teaching: "Leave one third of the belly with food, another third with drink and leave one third empty" (Tirmidhi) — aligns with caloric restriction research showing 30% restriction produces 50% reduction in spontaneous cancer incidence in primates.
Cell cycle arrest via p21, apoptosis through p53/Bax/caspase-3, Bcl-2 suppression, NF-κB downregulation across multiple cancer cell lines. The Prophet Muhammad ﷺ described black seed as "a cure for every disease except death." Modern pharmacology has spent decades confirming individual mechanisms that this statement encompassed 1,400 years ago.
Stanford's 2021 trial: high-fermented-food diet increased microbiota diversity and decreased 19 inflammatory markers including IL-6 in a 17-week randomised trial. [Wastyk et al., Cell, 2021]
Twenty years ago, if you said bacteria in your gut control your immune system, mental health, and cancer risk, mainstream medicine would have called you fringe. Now it is published in Nature and The Lancet. The establishment did not discover this. They caught up to what traditional food cultures had been practising for generations.
The Gutmann lab's 2025 finding that gut Bacteroides drives NF1-associated glioma growth through immune modulation means that what NF1 patients eat may directly influence whether their tumors grow. No pharmaceutical company will sell you a diverse microbiome. You build one with food.
Esposito T, et al. Nutrients. 2017;9(7):783. PMC5537897
Amaravathi A, et al. Front Oncol. 2021;11:698192. Frontiers
Haehnel V, et al. PLoS ONE. 2013;8(2):e57152. PMC3578816
Phase 1 Clinical Trial NCT05363267. ClinicalTrials
Lammert M, et al. J Med Genet. 2006;43(10):810-813. PMC2563168
Modica R, et al. Metabolites. 2023;13(2):255. MDPI
Yilmaz A, et al. Cureus. 2024. PMC11784969
Brunetti G, et al. Sci Reports. 2022. Nature
Summers MA, et al. Hum Mol Genet. 2018;27(4):577-588. Oxford Academic
Vasiljevski ER, et al. PLOS ONE. 2020;15(8):e0237097. PMC7446925
O'Donohue AK, et al. PLOS ONE. 2024. PLOS
Staser K, et al. Free Radic Biol Med. 2016;97:454-467. PMC5765860
Masgras I, et al. Antioxidants. 2023;12(8):1557. MDPI
Chung JY, et al. FASEB J. 2001;15(11):2022-2024. PubMed
Psahoulia FH, et al. Carcinogenesis. 2007;28(5):1021-1031. PubMed
Lee LT, et al. Mol Carcinogenesis. 2004;40(2):122-128. PubMed
Mashour GA, et al. Oncogene. 2005;24(14):2366-72. PubMed
Biotteau M, et al. Front Neurol. 2020;11:368. PMC7214842
Sabbagh A, et al. Hum Mol Genet. 2009;18(15):2768-2778. PubMed
Garza-Manero S, et al. Epigenetics & Chromatin. 2021;14(1):7. PMC7805211
Lawson ARJ, et al. Nature. 2025. DOI: 10.1038/s41586-025-09448-3
Over-transmission preprint. medRxiv 2025
Gutmann DH lab. Neuro-Oncology. 2025. DOI: 10.1093/neuonc/noaf024
Parker W, et al. Med Hypotheses. 2015;84(4):305-310. PubMed
Wastyk HC, et al. Cell. 2021;184(16):4137-4153. PMC9020749
Gross AM, et al. PMC9629437
Babaria DN, et al. Neuro-Oncology. 2024;26(Suppl 8):viii269. Oxford Academic
Griffin GE. World Without Cancer: The Story of Vitamin B17. American Media, 1974/1997.
Moss RW. The Cancer Industry. Equinox Press, 1980/1991.
Ibn Qayyim Al-Jawziyya. Al-Tibb al-Nabawiyy (Prophetic Medicine). 13th century.
McCarrison R. Nutrition and National Health. Faber & Faber, 1937.